The Project for Risk Identification of Immune-Mediated Adverse Events

The Project for Risk Identification of Immune-Mediated Adverse Events - PRIME study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033194

Enrollment

300

Registered

2018-07-01

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Neoplasm

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cance patients treated with immune checkpoint inhibitors (nivolumab, ipilimumab, pembrolizumab, avelumab, atezolizumab).

Exclusion criteria

Exclusion criteria: Patients with any condition, in the opinion of the investigator, have the limitation of ability to comply with the study requirements or impact the interpretability of study results.

Design outcomes

Primary

Measure	Time frame
Identification of specific autoantibodies	—

Countries

Japan

Contacts

Public ContactShunichiro Iwasawa

Department of Respirology, Graduate School of Medicine, Chiba University Department of advancing research on treatment strategies for respiratory disease (DARTS)

iwasawas@chiba-u.jp043-222-7171

Outcome results